Literature DB >> 28803353

Palliative care in ovarian carcinoma patients-a personalized approach of a team work: a review.

Yakir Segev1,2, Lior Segev3, Meirav Schmidt4, Ron Auslender4,5, Ofer Lavie4,5.   

Abstract

Most ovarian cancer patients are diagnosed in an advanced stage; and after the initial treatment experience disease recurrence, which eventually becomes palliative. Many questions arise in this setting including how to address patients in the palliative setting, how to discuss end-of-life issues, and how to manage symptoms. In this review, we discuss the timing and setting of end-of-life discussion in the context of end-stage ovarian cancer. We review the approach to relieving disease burden by improving and decreasing symptoms. These symptoms include recurrent ascites, bowel obstruction, pain, pulmonary effusion, and deep vein thrombosis.

Entities:  

Keywords:  Ascites; Bowel obstruction; Ovarian cancer; Pain; Palliative

Mesh:

Year:  2017        PMID: 28803353     DOI: 10.1007/s00404-017-4484-8

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  4 in total

1.  Centromere protein U facilitates metastasis of ovarian cancer cells by targeting high mobility group box 2 expression.

Authors:  Hongjuan Li; Hui Zhang; Yali Wang
Journal:  Am J Cancer Res       Date:  2018-05-01       Impact factor: 6.166

2.  Clinical Characteristics and Survival of Patients with Malignant Ovarian Tumors in Addis Ababa, Ethiopia.

Authors:  Swantje Piszczan; Dawit Desalegn; Hezkiel Petros; Mengistu Gurmu; Eric Sven Kroeber; Adamu Addissie; Rafael Mikolajczyk; Rahel G Ghebre; Assefa Mathewos; Christoph Thomssen; Ahmedin Jemal; Eva Johanna Kantelhardt
Journal:  Oncologist       Date:  2019-04-25

Review 3.  Sarcopenia: Clinical implications in ovarian cancer, diagnosis, etiology, and management.

Authors:  Aeran Seol; Se Ik Kim; Yong Sang Song
Journal:  Sports Med Health Sci       Date:  2020-10-14

4.  MiR-29c-3p, a target miRNA of LINC01296, accelerates tumor malignancy: therapeutic potential of a LINC01296/miR-29c-3p axis in ovarian cancer.

Authors:  Hui Xu; Hong-Luan Mao; Xin-Rui Zhao; Yue Li; Pei-Shu Liu
Journal:  J Ovarian Res       Date:  2020-03-19       Impact factor: 4.234

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.